Table 2.
Baseline patient characteristics of weekly exenatide and basal insulin cohorts (RWE study, after matching)
| Characteristic | Exenatide once weekly (n = 2008) | Basal insulin* (n = 4016) |
|---|---|---|
| Age group [n (%)] | ||
| ≤ 34 | 65 (3.2%) | 136 (3.4%) |
| 35‐44 | 215 (10.7%) | 433 (10.8%) |
| 45‐54 | 540 (26.9%) | 1079 (26.9%) |
| 55‐64 | 693 (34.5%) | 1416 (35.3%) |
| 65‐74 | 421 (21.0%) | 815 (20.3%) |
| ≥ 75 | 74 (3.7%) | 137 (3.4%) |
| Age (years) [mean (SD)] | 57.0 (9.2) | 56.9 (9.1) |
| Sex [n (%)] | ||
| Male | 1003 (50.0%) | 1979 (49.3%) |
| Female | 1005 (50.0%) | 2037 (50.7%) |
| Race/ethnicity [n (%)] | ||
| White | 1630 (81.2%) | 3277 (81.6%) |
| African American | 151 (7.5%) | 303 (7.5%) |
| Hispanic | 96 (4.8%) | 220 (5.5%) |
| Asian | 38 (1.9%) | 62 (1.5%) |
| Multiple | 31 (1.5%) | 41 (1.0%) |
| Unknown | 62 (3.1%) | 113 (2.8%) |
| Number of diabetes drug classes [n (%)] | ||
| 0 | 507 (25.2%) | 950 (23.7%) |
| 1 | 583 (29.0%) | 1186 (29.5%) |
| 2 | 568 (28.3%) | 1170 (29.1%) |
| 3+ | 350 (17.4%) | 710 (17.7%) |
| Body‐mass index (kg/m2) [n (%)] | ||
| ≤ 24 | 32 (1.6%) | 73 (1.8%) |
| 25‐29 | 276 (13.7%) | 503 (12.5%) |
| 30‐39 | 1108 (55.2%) | 2219 (55.3%) |
| 40+ | 592 (29.5%) | 1221 (30.4%) |
| Weight (kg) [mean (SD)] | 107.5 (0.5) | 107.9 (0.4) |
| Haemoglobin A1C (%) [n (%)] | ||
| ≤ 7 | 425 (21.2%) | 789 (19.6%) |
| >7‐9 | 1000 (49.8%) | 1936 (48.2%) |
| >9 | 583 (29.0%) | 1290 (32.1%) |
| Haemoglobin A1C (%) [mean (SD)] | 8.3 (1.0) | 8.5 (1.1) |
| Estimated GFR (ml/min) [n (%)] | ||
| Could not be estimated | 62 (3.1%) | 113 (2.8%) |
| ≥ 90 | 924 (47.5%) | 1873 (48.0%) |
| 60‐90 | 772 (39.7%) | 1528 (39.1%) |
| ≤ 60 | 250 (12.8%) | 502 (12.9%) |
| Estimated GFR [mean (SD)] | 85.7 (22.1) | 85.7 (25.6) |
| Any baseline hypoglycemia [n (%)] | ||
| No | 1917 (95.5%) | 3841 (95.6%) |
| Yes | 91 (4.5%) | 175 (4.4%) |
*
Insulin glargine or detemir.